{
    "nctId": "NCT04514159",
    "briefTitle": "A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer",
    "officialTitle": "A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Incidence and severity of adverse events from ZN-c5 in combination with abemaciclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years of age\n* Women can be peri- or postmenopausal, as defined by at least one of the following:\n\n  * Age \u2265 60 years;\n  * Age \\< 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and follicle-stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females;\n  * Documented bilateral oophorectomy;\n  * Must receive a gonadotrophin-releasing hormone agonist beginning at least 4 weeks prior to the first dose of study medication\n* Histologically or cytologically confirmed diagnosis of advanced adenocarcinoma of the breast\n* Estrogen receptor positive disease\n* Human Epidermal Growth Factor Receptor 2 negative disease\n* Measurable disease per Response Evaluation Criteria in Solid Tumors v1.1\n\nExclusion Criteria:\n\n* Prior therapy within the following windows:\n\n  * Tamoxifen, aromatase inhibitor, fulvestrant, or other anti-cancer endocrine therapy \\< 14 days;\n  * Any investigational drug therapy \\< 28 days or 5 half-lives (whichever is shorter)\n  * Any prior systemic chemotherapy regardless of the stop date, but the subject must have recovered to eligibility levels from prior toxicity\n* Prior treatment with CDK4/6 inhibitors\n* Unexplained symptomatic endometrial disorders (including, but not limited to, endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}